Exact Sciences (EXAS)
(Real Time Quote from BATS)
$57.18 USD
+0.82 (1.46%)
Updated Aug 15, 2024 09:58 AM ET
2-Buy of 5 2
D Value A Growth D Momentum B VGM
Brokerage Reports
Exact Sciences Corporation [EXAS]
Reports for Purchase
Showing records 281 - 300 ( 369 total )
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
We are initiating coverage with a Buy rating and a 12-month price target of $16.
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
REITS BUY DEMONSTRATING PROGRESS TOWARD COLOGUARD FDA APPROVAL.
Provider: CAPSTONE INVESTMENTS
Analyst: PUTNAM J
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
3Q12 Preview - Expecting Management to Help Assuage Market Fears - Anticipating Better Clarity on Pivotal Data Timing - Maintain NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Downgrading to NEUTRAL - Risk /Reward Unappealing
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
GAUGES IMPACT OF OBAMACARE TAX ON MEDICAL DEVICES COS.
Provider: CAPSTONE INVESTMENTS
Analyst: PUTNAM J
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
2Q12 Recap - Pivotal Trial Enrollment & Prevalence On Track - Expect Additional Validation Data in Oct
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
2Q12 Preview - Anticipating a Quiet 2Q As Pivotal Study
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
We are placing Exact Sciences under review due to the departure from the firm of covering analyst
Provider: RODMAN & RENSHAW, CO.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
What EXAS Owners Should Know About CPHD''s Proposed Colon Cancer Test - No Overlap with ColoGuard - Maintaining OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Clinical Trial Enrollment Nearly Complete - FDA Filing Next
Provider: CAPSTONE INVESTMENTS
Analyst: PUTNAM J
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Reiterates Buy - Sigmoidoscopy Still Not The Answer... Cologuard Is!
Provider: CAPSTONE INVESTMENTS
Analyst: PUTNAM J
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Medical Devices: Pending Legislation Will Increase FDA''s Reach Offset By Some Benefits
Provider: CAPSTONE INVESTMENTS
Analyst: PUTNAM J
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
COLOGUARD DEEP-C TRIAL ON TRACK TO CONCLUDE ENROLLMENT IN Q3 - BUY
Provider: CAPSTONE INVESTMENTS
Analyst: PUTNAM J
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
1Q12 Results In line - Selloff Related to Slightly Higher Burn
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z